ESTRO 2023 - Abstract Book

S2

Saturday 13 May

ESTRO 2023

Referrences 1. Bujko, K. et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer. Ann. Oncol. 27, 834–842 (2016). 2. Bahadoer, R. R. et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO). Lancet Oncol. 22, 29–42 (2021). 3. Jin, J. et al. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR). J. Clin. Oncol. 40, 1681–1692 (2022). 4. Conroy, T. et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23). Lancet Oncol. 22, 702–715 (2021). 5. Fokas, E. et al. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. J. Clin. Oncol. JCO.(2019). 6. Garcia-Aguilar, J. et al. Organ Preservation in Patients with Rectal Adenocarcinoma Treated with Total Neoadjuvant Therapy. J. Clin. Oncol. 18, (2022). 7. Zhang, X., Ma, S., Guo, Y., Luo, Y. & Li, L. Total neoadjuvant therapy versus standard therapy in locally advanced rectal cancer: A systematic review and meta-analysis of 15 trials. PLoS One 17, e0276599 (2022).

Teaching Lecture: Role of PET/CT for treatment planning optimisation in salvage prostate radiotherapy

SP-0004 Role of PET/CT for treatment planning optimisation in salvage prostate radiotherapy S. Supiot 1 1 Nantes Université, Radiation Oncology, Saint Herblain, France

Abstract Text Following radical treatment of localized prostate cancer, up to 30% of patients may relapse. At relapse, PET/CT using PSMA, Choline or Fluciclovine plays a major role in defining the site of relapse and therefore could modify radiotherapy prescription in terms of indication, dose or volume. We will discuss the role of PET/CT-guided radiotherapy as a salvage treatment in different clinical situations: prostate bed relapse, pelvic lymph node relapse, distant metastases and relapse in a previously irradiated region. Following prostatectomy, salvage prostate bed radiotherapy is advocated if the PSA rises above 0.2 ng/ml, and ideally below 0.5 ng/ml. In approximately 50% of cases, PSMA PET/CT can determine the site of relapse, frequently within the prostate bed. Is there a role for radiotherapy-dose intensification in macroscopic prostate bed relapse? As shown in the SAKK 09/10 trial, increasing the total dose to the prostate bed up to 70 Gy increases toxicity rates but does not improve biochemical relapse-free survival. However, retrospective series suggest that boosting the dose to the macroscopic nodule could improve biochemical control without increasing toxicity. Another intensification strategy is to combine salvage radiotherapy and radiosensitizing drugs such as novel androgen-receptor targeting agents. Ongoing trials will help determine the best strategy of radiotherapy in macroscopic prostate bed relapses. Other frequent sites of relapse following radical treatment are pelvic lymph nodes. High dose radiotherapy targeting oligoreccurent pelvic lymph nodes, using SBRT or elective pelvic nodal irradiation may increase tumor control at the cost of limited toxicity. The Oligopelvis GETUG P12 trial is a randomized phase 3 trial that compares 6-months Androgen – Depriving Therapy (ADT) alone to ADT + elective pelvic radiotherapy. The STORM PEACE 5 trial will determine if a boost dose to the PET/CT defined lymph nodes can increase tumor control. Early toxicity results of the STORM PEACE 5 trial did not show any increased toxicity and efficacy results are eagerly awaited. Prostate cancer may also relapse distantly to non-pelvic lymph nodes, bones or less frequently to visceral sites. Randomized phase 2 trials such as SABR-Comet, Oriole or Stomp, showed that SBRT targeting oligorecurrent metastases could delay the introduction of systemic treatments and increase progression-free survival. Several randomized phase 3 studies are ongoing, in order to prove that adding metastases-targeted SBRT to systemic treatment can improve survival. The rather recent advent of PET-CT tracers lead also to the discovery of local relapses within previously irradiated areas, such as the prostate or the prostate bed. In order to delay the need for a systemic treatment for these local relapses, salvage local therapies (surgery, cryotherapy, HIFU…) have been developed. More recently salvage reirradiation using brachytherapy or SBRT was shown to be feasible despite manageable toxicity, in small series of patients. Ongoing phase I/II trials will help determine the best radiotherapy strategies in theses clinical situation (dose, fractionation) and should provide prospective evidence of efficacy. To conclude, the development of novel PET/CT radiotracers completely changed staging of prostate cancer. However, the potential benefits of novel PET/CT radiotracers to improve the efficacy of radiotherapy remain to be determined in prospective randomized phase 3 trials. SP-0005 Pulmonary SBRT technical Practice: Results of the 2022 ESTRO survey A. Scaggion 1 , A. Carver 2 , K. Karlsson 3 , E. Dalqvist 3 , D. Jurado Bruggeman 4 , F.R. Giglioli 5 , S. Warren 6 , V. Staykova 7 , A. Jenko 8 , A. Swinnnen 9 , O. Blank 10 , N. Jornet 11 , P. Pietro 12 1 Veneto Institute of Oncology IOV - IRCCS, Medical Physics Department, Padova, Italy; 2 University Hospitals Birmingham NHS Foundation Trust, Department of Medical Physics, Birmingham, United Kingdom; 3 Karolinska University Hospital, Radiotherapy Physics and Engineering, Medical Radiation Physics and Nuclear Medicine, Stockholm, Sweden; 4 Institut Català d’Oncologia, Medical Physics and Radiation Protection Department, Girona, Spain; 5 AOU Città della Salute e della Scienza, Medical Physics Unit, Torino, Italy; 6 Northern Centre for Cancer Care, Freeman Hospital, Department of Medical Physics, Newcastle Upon Tyne, United Kingdom; 7 Guy's and St Thomas' NHS Foundation Trust, Radiotherapy Physics, London, United Kingdom; 8 Institute of Oncology Ljubljana, Department of Radiotherapy, Ljubljana, Slovenia; 9 GROW School for Oncology, Maastricht University Medical Centre+, Department of Radiation Oncology (Maastro), Maastricht, The Netherlands; 10 University Medical Center Schleswig-Holstein, Department of Radiation Oncology, Kiel, Germany; 11 Hospital Teaching Lecture: Survey results and systematic review of the dosimetry information in papers on SBRT clinical trials